Conference Reports for NATAP

Back

Reported by Jules Levin IDWeek Oct 26-30 New Orleans 2016     Direct Acting Anti-Viral Therapy for Chronic Hepatitis C Virus Infection Is Associated with Regression of Liver Fibrosis, Assessed by Serial Transient Elastography (Fibroscan) - (11/11/16)   Effectiveness of DAA Regimens in Genotype 1 HIV/HCV Coinfected Patients: An Analysis of the VA National Clinical Case Registry - (11/28/16)   Long-term Effects of [Omega-3] Ω:-3 Fatty Acids in HIV: a RCT - (11/09/16)   [Barriers to HCV Care] Expanded HCV Testing and Linkage to Care: Program Implementation to Overcome Barriers to Engagement in Care ....7% SVR rate..... from Jules: there remain persistent difficult barriers to HCV care in inner cities, very strong support services related to linkage to care are needed. - (11/09/16)   Mass Incarceration and Economic Inequality: the Impact of the Criminal Justice System on HIV Prevalence within Neighborhoods in the US - (11/09/16)   Using Home-Delivery Pharmacy Triples Odds of Viral Control in Cleveland Group - Mark Mascolini (11/07/16)   High Proportions With AIDS/Non-AIDS Cancers Remain Unsuppressed - Mark Mascolini (11/07/16)   Caution Advised on Long-Term PPIs Because of Link to Immune Activation With HIV - Mark Mascolini (11/07/16)   Viral Rebound Rate 22% in US Group--Higher in Blacks and With Lower CD4s - Mark Mascolini (11/07/16)   Polypharmacy in HIV+ 50 or Older Linked to Lower CD4s, Higher CVD Rate - Mark Mascolini (11/07/16)   Women Account for Virtually Half of New HIV in Bronx Group in Regular Care - Mark Mascolini (11/07/16)   The Impact of Antiretroviral Tablet Burden and Polypharmacy on Viral Suppression in Treatment Naïve Patients - (11/07/16)   Efficacy of Dolutegravir/Abacavir/Lamivudine (ABC/DTG/3TC) Fixed Dose Combination (FDC) compared with Ritonavir Boosted Atazanavir (ATV/r) plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naïve Women with HIV-1 Infection (ARIA Study): Analyses by Race Subgroups - (11/07/16)   Renal and Bone Outcomes Among HIV-Infected Patients Exposed to EFV+TDF/FTC Compared to Other TDF-Containing Antiretroviral Regimens: Findings From the Veterans Health Administration - (11/07/16)   The ART Advantage: healthcare utilization for diabetes and hypertension in rural South Africa - (11/07/16)   HIV Reservoir Half-Life 12 Years in 111-Person, 477-Sample Analysis [slow decay] - - Mark Mascolini (11/05/16)   An expanded HIV testing strategy leveraging the electronic medical record uncovers undiagnosed infection among hospitalized patients - (11/05/16)   Almost Half of Atlanta MSM Will Use PrEP, But HIV Risk Perception Often Faulty - Willingness to Use Pre-exposure Prophylaxis (PrEP) among black and white MSM in Atlanta, GA - Mark Mascolini (11/04/16)   Prison Release, Poverty, Inequality Tied to Higher HIV Prevalence - Mark Mascolini (11/04/16)   New HIV Diagnoses Quadruple With Electronic Testing Prompt in Bronx Hospitals - Mark Mascolini - (11/04/16)   HIV Reservoir Half-Life 12 Years in 111-Person, 477-Sample Analysis - Mark Mascolini - (11/04/16)   Using Home-Delivery Pharmacy Triples Odds of Viral Control in Cleveland Group - Evaluation of impact of pharmacy proximity on HIV viral suppression - Mark Mascolini - (11/04/16)   Retesting of suspected low-level HIV-1 viral load blips: A new paradigm to prevent extra clinic visits and unnecessary patient anxiety - (11/04/16)   Detectable Viral Load--But Not PI Use--Linked to Avascular Necrosis - Risk Factors Associated With Osteonecrosis of the Hip in an HIV-Infected Population in the New Antiretroviral Therapy Era - Mark Mascolini - (11/04/16)   Should Anal Cancer Screening Get More Aggressive for Some MSM With HIV? - HPV-related disease in HIV-infected MSM with and without recent HCV - Mark Mascolini - (11/04/16)   HIV Infection and PrEP Use are Independently Associated with Increasing Diagnoses of Bacterial Sexually Transmitted Infections (BSTI) in Men Accessing Care at a Boston Community Health Center (CHC): 2005-2015 - (11/04/16)   Algorithm Sifting Medical Records May Predict Best PrEP Candidates - Automated Identification of Potential Candidates for HIV Pre-Exposure Prophylaxis using Electronic Health Record Data - Mark Mascolini - (11/04/16)   Emergence of HIV-1 Drug Resistance Through Week 48 in the Global Women's WAVES Study: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs. Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF - (11/04/16)   Efficacy and Safety of Tenofovir Alafenamide in HIV-Infected Black Adults: Subgroup Analysis of a Randomized, Double-blind Switch Study - (11/04/16)   Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir DF in HIV-Infected Virologically Suppressed Older Adults at Week 48: Subgroup Analysis of a Randomized Switch Study (Study 311-1089) - (11/04/16)   Sofosbuvir/Velpatasvir Plus Voxilaprevir for 6, 8, or 12 Weeks in Genotype 1-6 HCV-infected Patients: An Integrated Analysis of Safety and Efficacy from Two Phase 2 Studies - (11/04/16)   Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy - (11/03/16)   Depression and HIV Infection are Associated with Higher Risks of All-Cause Mortality in U.S. Veterans - Depression Adds to Mortality Risk With HIV in Large US Veterans Cohort - Mark Mascolini (11/03/16)   Long-term use of proton pump inhibitors and increased immune activation in patients with chronic HIV-1 infection Contact Information - Caution Advised on Long-Term PPIs Because of Link to Immune Activation With HIV - Mark Mascolini (11/03/16)   Assessing the needs of older HIV+ adults; Initial data from the CORE Healthy Aging Initiative (CHAI) - Money, Mental Health, Housing Top List of Concerns in Older HIV+ Chicago Group - Mark Mascolini (11/03/16)   Uptake and virologic outcomes of one-pill versus multi-pill antiretroviral regimen among treatment-naïve non-perinatally HIV-infected youth (2006-2014) - One-Pill ART Promotes HIV Control in US Youth--But Uptake Lower in Girls/Women - Mark Mascolini (11/03/16)   Sofosbuvir/Velpatasvir Plus Voxilaprevir for 6, 8, or 12 Weeks in Genotype 1-6 HCV-infected Patients: An Integrated Analysis of Safety and Efficacy from Two Phase 2 Studies - (11/03/16)   Uptake and virologic outcomes of one-pill versus multi-pill antiretroviral regimen among treatment-naïve non-perinatally HIV-infected youth (2006-2014) - One-Pill ART Promotes HIV Control in US Youth--But Uptake Lower in Girls/Women - Mark Mascolini - (11/02/16)   A Longitudinal Analysis of Comorbidities among Human Immunodeficiency Virus (HIV) Patients and Matched non HIV Controls in the USA - (11/02/16)   Fourteen-Study Analysis Summarizes Safety of Injected and Oral Cabotegravir - Cabotegravir (CAB) Safety Meta-analysis Update From 14 Phase I/IIa Studies - Mark Mascolini - (11/02/16)   [11%] One in 10 MSM in Care for HIV Screened for Anal Cancer--Rate Lower in Blacks - Mark Mascolini - (11/02/16)   Monotherapy With Anti-CD4 Monoclonal Antibody Cuts Viral Load 10-Fold in 7 Days - Mark Mascolini - (10/31/16)   One Third of HIV Group With Statin Indication Not Getting Statins - - Mt Sinai NYC, Optimizing Cardiovascular Risk Prevention in an Urban HIV Clinic - Mark Mascolini - (10/31/16)   [35% Taking 12 Comedications !] - Polypharmacy in HIV+ 50 or Older Linked to Lower CD4s, Higher CVD Rate - Evaluating the Effect of Polypharmacy on Outcomes in HIV-Infected Patients Age 50 and Older - Mark Mascolini - (10/31/16)   TWO REPORTED CASES OF ONLY PRIMARY INTEGRASE INHIBITOR DRUG-CLASS RESISTANCE TRANSMISSION INCLUDING THE FIRST REPORTED CASE OF PRIMARY ELVITEGRAVIR RESISTANCE TRANSMISSION - (10/31/16)   Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients with Multi-Drug Resistant HIV-1 Infection - (10/31/16)   Past Substance Use Affects CNS Inflammation In HIV - (10/31/16)   Low Endothelial Progenitors Tied to CVD Risk, Activation in Older HIV+ Men - Endothelial Progenitor Cell Production is Suppressed and Associated with Systemic Inflammation and Monocyte Activation in Older HIV-Infected Men - Mark Mascolini - (10/31/16)   Meta-Analysis Sees Much Higher STI Risk in MSM On vs Not On PrEP - Mark Mascolini - (10/31/16)